Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation (BREAST-HDCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02860585
Recruitment Status : Completed
First Posted : August 9, 2016
Last Update Posted : September 26, 2017
Sponsor:
Information provided by (Responsible Party):
Institut Paoli-Calmettes

Brief Summary:
The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.

Condition or disease
Breast Neoplasms

Layout table for study information
Study Type : Observational
Actual Enrollment : 235 participants
Observational Model: Cohort
Time Perspective: Retrospective
Actual Study Start Date : September 27, 2013
Actual Primary Completion Date : February 29, 2016
Actual Study Completion Date : February 29, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer




Primary Outcome Measures :
  1. Overall Survival according to Immunohistochemical subtypes . [ Time Frame: 8 years ]

Secondary Outcome Measures :
  1. Progression free Survival according to Immunohistochemical subtypes . [ Time Frame: 8 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
female patients treated for Metastatic breast Cancer with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation at the Institut Paoli-Calmettesbetween 2003 and 2012
Criteria

Inclusion Criteria:

  • Age>18 years
  • Metastatic breast Cancer
  • Treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation between 2003 and 2012

Exclusion Criteria:

  • Lack of follow-up data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02860585


Locations
Layout table for location information
France
Institut Paoli-Calmettes
Marseille, France, 13009
Sponsors and Collaborators
Institut Paoli-Calmettes
Investigators
Layout table for investigator information
Study Director: Christian Chabannon, MD,PhD Institut Paoli-Calmettes
Principal Investigator: Anthony Gonçalves, MD,PhD Institut Paoli-Calmettes
Layout table for additonal information
Responsible Party: Institut Paoli-Calmettes
ClinicalTrials.gov Identifier: NCT02860585    
Other Study ID Numbers: BREAST-HDCT-IPC 2014-001
First Posted: August 9, 2016    Key Record Dates
Last Update Posted: September 26, 2017
Last Verified: August 2016
Keywords provided by Institut Paoli-Calmettes:
Metastatic breast cancer
high-dose chemotherapy
autologous haematopoietic progenitor cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases